Innovate or die & Sustainability is everyone’s business!
Those were some of the headlines in our top-notch four day Master Class Business Innovation in Life Science program provided by Atrium Copenhagen (The Danish Association of the Pharmaceutical Industry) and CBS Executive Fonden for a group of ambitious and curious pharma executives and experts. As a course leader, I was excited to see the high level of engagement and enthusiasm from participants in the sessions.
In part 1 researchers from Copenhagen Business School provided excellent research and concrete tools in the fields of innovation leadership, and ESG and Sustainability. This combined with high-level practitioners who shared the big picture as well as concrete cases on how pharma and hospital systems are working on ESG matters. Last but not least, an eye-opening key-note by Kasim Kutay, CEO of Novo Holdings, who lead us into the challenges of pharma businesses. He stressed the need for pharma to think and work differently to mitigate present and future markets and global health:
* Open up for external collaborations, licensing, and mergers and acquisitions
* Focus on Gen. AI, digitalization and quantum
* Focus on Preventative Medicine for earlier treatment
* Access to drugs worldwide
In part 2 we focused on:
@ AI and Data Science as enablers for innovation in pharma and across the life sciences value chain. Including the patient’s perspective and ethics.
@ The increasing role of Public-Private Innovation collaborations and Strategic Partnerships as value creators in Life Science. Including how to be an attractive partner. Many thanks to thought leaders from Microsoft, Novo Nordisk, Roche, Innovation at Bispebjerg Hospital and Danish Life Science Cluster for sharing insights and state of the art cases.
